Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Acta Pharmacologica Sinica

• Publication date

  2017-08-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/aps.2017.107PMID 28795691PMCID PMC5672066
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A systematic literature review on Wikidata

  2019cited by this paper
• American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

  2017cited by this paper
• Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells

  2016cited by this paper
• RET/PTC Rearrangements Are Associated with Elevated Postoperative TSH Levels and Multifocal Lesions in Papillary Thyroid Cancer without Concomitant Thyroid Benign Disease

  2016cited by this paper
• Mouse models of medullary thyroid cancer and developing new targeted therapies

  2016cited by this paper
• Recent Updates on the Management of Medullary Thyroid Carcinoma

  2016cited by this paper
• Effects and Role of Multikinase Inhibitors in Thyroid Cancer.

  2016cited by this paper
• Cancers of the Thyroid: Overview and Statistics in the United States and Oklahoma.

  2016cited by this paper
• Lenvatinib: Role in thyroid cancer and other solid tumors.

  2016cited by this paper
• A cohort study on 10‐year survival of sporadic medullary thyroid carcinoma with somatic RET mutation

  2016cited by this paper
• Targeted therapies in advanced differentiated thyroid cancer.

  2015cited by this paper
• The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.

  2014cited by this paper
• The discovery and development of vandetanib for the treatment of thyroid cancer

  2014cited by this paper
• Is there really an increased incidence of thyroid cancer?

  2014cited by this paper
• Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

  2014cited by this paper
• Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.

  2014cited by this paper
• Clinical, Safety, and Economic Evidence in Radioactive Iodine–Refractory Differentiated Thyroid Cancer: A Systematic Literature Review

  2013cited by this paper
• Advanced medullary thyroid cancer: pathophysiology and management

  2013cited by this paper
• Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.

  2013cited by this paper
• Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer.

  2013cited by this paper
• Reciprocal epithelial:endothelial paracrine interactions during thyroid development govern follicular organization and C-cells differentiation.

  2013cited by this paper
• Intracellular Signal Transduction and Modification of the Tumor Microenvironment Induced by RET/PTCs in Papillary Thyroid Carcinoma

  2012cited by this paper
• New Treatment in Advanced Thyroid Cancer

  2012cited by this paper
• The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts

  2012cited by this paper
• New Insight into the Treatment of Advanced Differentiated Thyroid Cancer

  2012cited by this paper
• AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR

  2012cited by this paper
• New Molecular Targeted Therapy and Redifferentiation Therapy for Radioiodine-Refractory Advanced Papillary Thyroid Carcinoma: Literature Review

  2012cited by this paper
• Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.

  2011cited by this paper
• XL184 (cabozantinib) for medullary thyroid carcinoma

  2011cited by this paper
• E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.

  2011cited by this paper
• Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma.

  2011cited by this paper
• Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

  2010cited by this paper
• New molecular targeted therapies integrated with radiation therapy in lung cancer.

  2010cited by this paper
• 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

  2009cited by this paper
• Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

  2009cited by this paper
• Recent advances in molecular biology of thyroid cancer and their clinical implications.

  2008cited by this paper
• Thyroid carcinoma: molecular pathways and therapeutic targets

  2008cited by this paper
• Motesanib diphosphate in progressive differentiated thyroid cancer.

  2008cited by this paper
• Motesanib diphosphate in progressive differentiated thyroid cancer.

  2008cited by this paper
• Thyroid carcinoma.

  2007cited by this paper
• RET receptor signaling: Dysfunction in thyroid cancer and Hirschsprung's disease

  2006cited by this paper
• Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.

  2005cited by this paper
• RET tyrosine kinase signaling in development and cancer.

  2005cited by this paper
• American

  1898cited by this paper

• A novel STING agonist with systemic and durable anti‐tumour activity

  2023cites this paper
• Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment

  2021cites this paper
• PI3Kα inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma

  2021cites this paper
• Mouse Models of Thyroid Cancer: Bridging Pathogenesis and Novel Therapeutics.

  2020cites this paper
• A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated

  2020cites this paper
• 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

  2009cites this paper